Month: April 2021

Til Nasdaq Copenhagen 12. april 2021   Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Totalkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 9. april 2021 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/investor-relations/regnskabsaflaggelse/Ekstraordinare-indfrielser/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Totalkredit A/S                       Vedhæftede filerEkstraordinære_indfrielser_Totalkredit_2021-04-12_DA eordindftk_2021-04-12

67% overall response rate and 19% complete response rate in 21 patients All complete responders remained in remission at time of data cut-off DALLAS, April 12, 2021 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, presented clinical data from a compassionate use program for the treatment of metastatic melanoma at the American Association for Cancer Research (AACR) virtual meeting April 10 – 15, 2021. The presentation abstract and additional information is available on the AACR conference web site at www.aacr.org. “Despite the recent advances in immunotherapy for solid tumors, many patients do not receive clinical benefit or experience relapse after an initial remission,”...

First Radisson Individuals in the Baltics opens its doors in Tallinn With an excellent location at the entrance to the Old Town, Radisson Hotel Group is delighted to announce the opening of Palace Hotel Tallinn, a member of Radisson Individuals. Built almost 100 years ago and respectfully renovated, this monument of national architectural heritage is the first Radisson Individuals in the Baltic region.    Palace Hotel Tallinn, a member of Radisson Individuals offers 79 rooms and suites, including a Presidential Suite stretching across 150 m2 which consists of a large studio with seating area for eight guests, a kitchen area with dining table for six, sauna, private office and meeting room. The hotel’s 50 m2 air-conditioned fitness center is equipped with large mirrors and cardiovascular machines by LifeFitness as well as an indoor swimming...

C4X Discovery Holdings plc Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme €7 million upfront payment in addition to potential pre-clinical milestones of €11 million,clinical and commercial milestones plus royalties Second major licensing deal with a global pharmaceutical company in commercially attractive markets 12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with Sanofi (NASD: SNY, PAR: SAN – “Sanofi “), worth up to €414 million, for C4XD’s oral pre-clinical IL-17A inhibitor programme.  Under the terms of the agreement, C4XD will receive an upfront payment...

PETAH TIKVA, Israel, April 12, 2021 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today announced that it will release its first quarter 2021 financial results on Tuesday, May 4, 2021. Conference Call and Webcast Following the release, Adi Sfadia, Chief Executive Officer, and Bosmat Halpern, Chief Financial Officer, will discuss Gilat’s first quarter 2021 results and business achievements and participate in a question and answer session: Date:      Tuesday, May 4, 2021Start:      09:30 AM EDT / 16:30 ISTDial-in:   US: 1-866-744-5399              International: (972) 3- 918-0610A simultaneous webcast of the conference call will be available on the Gilat website at www.gilat.com and through this link: www.veidan-stream.com/gilatq1-2021.html The...

Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) — Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies. RNAscope®in situ hybridization (ISH) is a new Interpace offering that can visualize, localize, and quantify gene expression within a single assay. RNAscope® ISH utilizes unique “double Z” probes which can simultaneously provide signal amplification and background noise control, resulting in high sensitivity and specificity. Additionally, single-molecule visualization of the assay yields quantitative RNA expression and cell-specific expression within intact tissue architecture. Application of RNAscope® ISH can streamline immune checkpoint target identification; visualize...

LOS ANGELES, April 12, 2021 (GLOBE NEWSWIRE) — Foothills Exploration, Inc. (OTC: FTXP), including its direct and indirect subsidiaries, (“Foothills,” or the “Company”), an oil and gas exploration company, is pleased to announce that it has been invited to present at the Emerging Growth Conference on April 14, 2021. Foothills invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. The next Emerging Growth Conference is presenting on April 14, 2021. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s Executive Vice President of Finance and Investor Relations Officer, Mr. Christopher C. Jarvis in real time. Mr....

SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years Contraceptive potential of relugolix combination tablet supported by prior Phase 1 study that demonstrated 100% ovulation inhibition Data would support a potential indication of pregnancy prevention for women treated with relugolix combination tablet, if approvedBASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in healthy women ages 18-35 years who...

NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) — Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI) and Jefferson Energy Companies (“Jefferson Energy”) are pleased to announce the successful completion of the Southern Star pipeline project. This project consists of a 24-inch crude oil pipeline connecting the Jefferson Energy terminal to the Motiva Port Neches terminal in Port Neches, TX. The Southern Star pipeline allows for ratable and efficient oil pipeline movements between the two locations and provides pipeline throughput capacity up to 288,000 barrels per day of light and heavy crude oil. Through premium design engineering and construction techniques, the pipeline can flow oil with an API as low as 15 degrees allowing for pipeline movements of blended and straight run crude oils. Jefferson Energy expects crude...